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Abstract
The Seeplex™ TB Detection-2 assay (Rockville, MD) is a nested endpoint PCR for the
Mycobacterium tuberculosis complex (MTBC) targets IS6110 and MPB64 that utilizes dual priming
oligonucleotide technology. When used to detect the presence of MTBC DNA in formalin-fixed
paraffin-embedded tissue specimens, the sensitivity and specificity of this assay is equivalent to a
labor-intensive traditional endpoint PCR assay and is more sensitive than a commercial real-time
PCR assay.
Findings
Since December of 2000, the Central Public Health Labo-
ratory (CPHL) of the Ontario Public Health Laboratories,
Ministry of Health and Long-Term Care has utilized an in-
house nucleic acid amplification testing followed by
Sanger sequencing for the detection of Mycobacterium
tuberculosis complex (MTBC) in formalin-fixed paraffin-
imbedded tissue specimens. Although this methodology
has allowed for the characterization of approximately 250
tissue specimens, it is labor intensive and requires the use
of an expensive sequencing protocol to ensure assay spe-
cificity. During this time, several commercial kits and
other published methodologies have become available
which allow for the molecular diagnosis of MTBC in
biopsy specimens and utilize specific mechanisms to
ensure assay specificity. The targets of these assays include
IS6110 [1] and MPB64 [2] using either traditional end-
point PCR or real-time PCR.
Traditional endpoint PCR is often thought to lack the ana-
lytical sensitivity and specificity when compared to real-
time PCR technology [3,4]. Although real-time PCR may
offer increased sensitivity and specificity, several articles
have described failures of real-time PCR assays to detect
MTBC due to slight changes in primer and probe
sequences [5]. When using end-point PCR reactions, spe-
cificity can be increased through the use of sequencing
technology or restriction enzyme analysis of PCR prod-
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ucts. Dual-priming oligonucleotide technology (DPO)
has also been recently described in the literature as a
method that increases both the sensitivity and specificity
of endpoint PCR reactions [6]. As a result, this methodol-
ogy provides a means of confirming sequences without
the requiring real-time PCR or extensive processing of
PCR products for use in sequencing reactions or restric-
tion enzyme analysis [6]. Recently, a commercial DPO-
based assay (Seegene, Rockville, MD) utilizing nested PCR
for MTBC specific target genes IS6110  and MPB64,
became available.
This manuscript describes the verification of the Seeplex™
TB Detection-2 assay (Seegene, Rockville, MD) and the
artus® M. tuberculosis TM assay (Qiagen, Mississauga, ON,
Canada) on formalin-fixed paraffin-embedded tissue
specimens that had been previously tested using the in-
house assay, and an analysis of the turn-around-time
(TAT) and workflow required for performance of the
assays [1].
Purified M. tuberculosis H37Rv DNA was used as standard
for analysis of limit of detection for multiple methods.
Theoretical limits of detection for each methodology were
determined using serial 10-fold dilutions of M. tuberculosis
H37Rv DNA in PCR grade water. The theoretical number
of copies of M. tuberculosis H37Rv DNA was calculated
according to a generally accepted conversion formula.
Formalin-fixed paraffin-embedded tissue sample blocks
are submitted to the CPHL with a copy of the correspond-
ing histopathology report. Depending of the size of the
tissue block, either the entire tissue, or portions of the tis-
sue block (determined histopathologically) were de-par-
affinized and DNA extraction prepared using QiaAMP
spin column (QIAGEN, Mississauga, Ontario) protocol
[7]. DNA was frozen at -80°C until further use in PCR pro-
tocols.
The in-house reference method was a modification of a
previously published method [1] and has been used as a
diagnostic tool at the authors' facility since December
2000. Briefly, 5 μl of extracted DNA were used in a non-
nested PCR reaction utilizing the DNA minikit (QIAGEN,
Mississauga, Ontario) procedure, 0.3 μM primer IS-1 (5'-
CCT GCG AGC GTA GGC GTC GG-3') and 0.3 μM IS-2
(5'-CTC GTC CAG CGC CGC TTC GG-3') using the PCR4
reaction (one 4 minute denaturation step at 95°; 45 cycles
of 30 seconds at 95°C, 30 seconds at 63°C, 30 seconds at
72°C; and a 7 minute extension at 72°C) [1]. In addition,
amplicons of the appropriate molecular mass were identi-
fied by EtBr staining of a 1% agarose gel electrophoresis
and due to the presence of some non-specific banding,
amplicons of the appropriate size were confirmed by
Sanger sequence analysis using the ABI BigDye® Termina-
tor v3.1 Cycle Sequencing Kit on an ABI 3100 genetic ana-
lyzer (Applied Biosystems, Foster City, CA). IS6110
sequences were compared to accessioned sequences using
the Basic Local Alignment Search Tool (BLAST) and the
NCBI database http://www.ncbi.nlm.nih.gov/blast/
Blast.cgi. Sequences were considered to be identified as
IS6110 if they shared the highest identity in the BLAST
search. Amplicons were also restricted by 10 units of SalI
(New England Biolabs, Ipswich, MA) at 37°C for 3 hours.
Digested amplicons were analyzed by 3% agarose gel elec-
trophoresis and EtBr staining. DNA from the control
strain MT14323 was spiked into the clinical specimens
that had negative results to determine if this was a result
of PCR inhibition [8].
To control for DNA extraction, all specimens that were
negative for IS6110 by the uninhibited reference in-house
PCR method were assayed for the human gene gapdh
using a commercial gapdh assay kit and an ABI 7900 HT
thermocycler (Applied Biosystems, Foster City, CA).
Between May 2007 and January 2008, DNA from speci-
mens was first extracted from formalin-fixed paraffin-
embedded tissue blocks and tested against the in-house
reference method. DNA from specimens that were deter-
mined to be either positive or negative by the reference
method were frozen at -80°C until further analysis. It
should be noted that DNA from specimens that were pos-
itive by the in-house reference method were also con-
firmed to be positive by sequencing of IS6110 product
fragments.
DNA extracted from the formalin-fixed paraffin-embed-
ded tissue blocks from 21 IS6110- positive and 35 IS6110-
negative specimens by the reference method was concur-
rently analyzed by two commercially available methods,
the Seeplex™ TB Detection-2 assay (Seegene, Rockville,
MD) and the artus® M. tuberculosis TM PCR assay (for use
with the ABI 7900 HT as per manufacturer's protocols).
The amount of DNA used varied as per the kit/assay man-
ufacturer's instructions. Inputs for each assay used were as
follows: Seeplex™ TB detection-2 assay utilized 3 μl for ini-
tial and nested PCR reactions; artus® M. tuberculosis TM
PCR kit, 10 μl. Results were compared to the in-house
assay results.
The Seeplex™ TB Detection-2 assay was carried out using
an iCycler (Bio-Rad, Hercules, CA) and 1% agarose gel
electrophoresis and EtBr staining for amplicon detection.
This assay contains an integrated control for PCR inhibi-
tion. The Seeplex™ TB Detection-2 is a nested PCR involv-
ing a first run PCR (1 at cycle 94°C for 15 minutes; 35
cycles at 94°C for 30 seconds, 60°C for 30 seconds, 72°C
for 30 seconds; 1 cycle at 72°C for 5 minutes) and a
nested PCR (1 cycle at 94°C, 15 minutes; 25 cycles atDiagnostic Pathology 2008, 3:37 http://www.diagnosticpathology.org/content/3/1/37
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94°C for 30 seconds, 62°C for 30 seconds, 72°C 30 sec-
onds; 1 cycle at 72°C for 5 minutes). The artus® M. tuber-
culosis TM PCR kit followed the assay protocol with the
following protocol: 1 cycle 95°C for 2 minutes; 45 cycles
at 95°C for 15 seconds; and 64°C for 1 minute. In the
event of internal control inhibition, total nucleic acids
from specimens were diluted 1/10 and 1/100 in PCR
grade dH20 and re-tested as per each assay protocol.
The time required to complete different methods was
compared by a retrospective review of work flow from lab-
oratory records. Chi-squared analysis was carried out
using GraphPad Prism software (GraphPad Software Inc.,
El Camino Real, CA). Probit regression analysis was car-
ried out using SPSS 15 software (SPSS Inc., Chicago, IL).
Thirty-five specimens that were negative by the in-house
reference method were tested by the two commercial
methods. All specimens demonstrated successful DNA
extraction as all specimens were gapdh-positive. The pro-
portions and numbers of formalin-fixed paraffin-embed-
ded tissues per specimen type were as follows: pulmonary
(46%, 16/35), lymphatic (23%, 8/35), gastrointestinal
(14%, 5/35), musculoskeletal (6%, 2/35), central nervous
system (6%, 2/35), endothelial (3%, 1/35), and integu-
ment (3%, 1/35).
Twenty-one specimens that were positive by the in-house
reference method were tested by the two commercial
methods. All specimens demonstrated successful DNA
extraction as all specimens were gapdh-positive. The pro-
portions and numbers of formalin-fixed paraffin-embed-
ded tissues per specimen type were as follows: lymphatic
(33%, 7/21), pulmonary (24%, 5/21), genitourinary
(14%, 3/21), musculoskeletal (14%, 3/21), central nerv-
ous system (5%, 1/21), gastrointestinal (5%, 1/21), and
integument (5%, 1/21). There was no significant differ-
ence between proportion of specimen types in positive
and negative specimens when analyzed for pulmonary,
lymphatic and a combination of all other specimens (χ2 =
2.697, df = 2, p = 2.697).
Table 1 details the performance characteristics of each
assay to identify MTBC in formalin-fixed paraffin-embed-
ded human tissue specimens. The in-house IS6110 PCR,
sequencing, and restriction analysis were used as the refer-
ence standard for specificity and sensitivity analyses. Inhi-
bition of PCR occurred in 10/35 (29%) reference test
negative specimens tested by the artus® M. tuberculosis
MTB assay. Specimens were re-tested after dilution of
extracted nucleic acid in 1/10 dH20, with all but one spec-
imen being resolved. The one unresolved specimen
remained inhibited even after a 1/100 dilution of
extracted DNA in dH20. Removing the inhibited negative
specimen from analysis, the specificity of the artus® M.
tuberculosis TM PCR kit was 100% (34/34). In contrast, 6%
(2/35) of reference test negative specimens were initially
inhibited when the Seeplex™ TB Detection-2 kit was used
on specimens. It should be noted that both of these spec-
imens were also inhibited when tested by the artus® M.
tuberculosis MTB assay. All of these inhibited specimens
were resolved by 1/10 dilution of the extracted nucleic
acid in dH20. Inhibition of PCR reactions varied between
assays. The specificity of the Seeplex™ TB Detection-2 kit
when compared to IS6110 PCR, sequencing and restric-
tion analysis was (35/35) 100%.
Inhibition of PCR occurred in 5/21 (24%) of reference test
positive specimens using the artus® M. tuberculosis TM PCR
kit. Inhibition could not be overcome by 1/10 and 1/100
dilution of nucleic acid in dH20. Although inhibition
could be resolved in four of five specimens by dilution of
nucleic acid in 1/10 dH20, these dilutions failed to iden-
tify MTBC targets in these specimens. Thus, due to assay
inhibition and attempts to overcome this inhibition, only
76% (16/21) of positive specimens were detected by the
artus® M. tuberculosis TM PCR assay. When inhibited spec-
imens that failed to resolve were discarded from analysis,
the sensitivity of the artus® M. tuberculosis TM PCR kit was
80% (16/20). In contrast, none of the positive specimens
were inhibited when the Seeplex™ TB Detection-2 kit was
utilized. Although the sensitivity of the Seeplex™ TB
Detection-2 kit was 95% (20/21) (Table 1) the single dis-
Table 1: Relative test performance of two commercia1 assays for MTB complex detection in formalin-fixed parafinized biopsy 
specimens.
Result Methodology
artus® M. tuberculosis TM PCR Seeplex™ TB Detection-2 assay
% (#) inhibited negative* specimens (n = 35) 29 (10) 6 (2)
% 
(#) total negative* specimens with resolved inhibition (n = 35)
97 (34) 100 (35)
% (#) inhibited positive* specimens (n = 21) 24 (5) 0 (0)
% 
(#) total positive* specimens with resolved inhibition (n = 21)
76 (16) 95 (20)
*as determined by reference method (IS6110 PCR, sequence analysis, and restriction enzyme analysis)Diagnostic Pathology 2008, 3:37 http://www.diagnosticpathology.org/content/3/1/37
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cordant specimen was only positive by the reference
method, and was also unresolved using the artus® M.
tuberculosis TM PCR kit.
The limit of detection of M. tuberculosis H37Rv as deter-
mined by Probit regression (95% probability) for each
methodology was estimated to be; Seeplex™ TB Detection-
2 assay (0.4 genome copies per reaction), artus® M. tuber-
culosis TM PCR assay (10 genome copies per reaction) and
the in-house assay (0.2 genome copies per reaction).
Based on an average 7.5 h workday, specimen extraction
and the in-house reference assay had an approximate TAT
of 72 hours. Including specimen extraction time, the
approximate TAT for the Seeplex™ TB Detection-2 kit was
6 hours while the average TAT for the artus® M. tuberculosis
TM PCR was 4 hours. The estimated average cost per spec-
imen by the three methods in Canadian dollars was as fol-
lows: artus® M. tuberculosis TM PCR at $40, Seeplex™ TB
Detection-2 kit at $15, and the in-house reference assay at
$5.
The artus® M. tuberculosis TM PCR kit is a closed, real-time
system assay with less requirement for manual manipula-
tion, but had problems with inhibition and decreased
sensitivity when compared to the in-house reference
method. The poor performance of this assay when com-
pared to the Seeplex™ TB Detection-2 assay may be a prod-
uct of the interaction between PCR kit, specimen and
extraction method. The sensitivity of the artus® M. tubercu-
losis TM PCR kit may be negatively affected by the higher
limit of detection (10 genome copies per reaction) when
compared to 0.4 genome copies per reaction for the
nested Seeplex™ TB Detection-2 assay and 0.2 genome
copies per reaction for the non-nested reference method.
Thus, in some specimens, dilutions of DNA used to over-
come the inhibitory nature of the matrix used in this study
(e.g. in formalin-fixed paraffin-imbedded tissue speci-
mens) may have forced the concentration of MTBC DNA
below the limit of detection of the assay. It is also possible
that some factors such as small changes in real-time
primer and probe design may also have an effect on the
relative poor performance of the real-time PCR kit. Given
these multiple effects, the authors believe that the artus®
M. tuberculosis TM PCR kit may have improved test charac-
teristics with less complex specimens (e.g. fresh tissue) or
an extraction method capable of removing assay inhibi-
tors.
In conclusion, the Seeplex™ TB Detection-2 kit offers
equivalent sensitivity and specificity to a more labor-
intensive endpoint PCR method and improved sensitivity
when compared to a commercial real-time product. The
presence of an internal control directly within this assay
allows for the determination of PCR inhibition when test-
ing these potentially inhibited specimens.
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